



PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

## CERTIFICATE OF MAILING

I hereby certify that this **INFORMATION DISCLOSURE STATEMENT** and documents submitted therewith are being deposited with the United States Postal Service as first class mail, postage prepaid thereon, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date indicated below.

Bethany Crandell  
Bethany Crandell

4/11/2007  
Date

Applicant: Bracey, et al.	) Group: Unassigned
Serial No.: 10/534,766 ✓	) Confirmation No.: 8883
Filed: May 12, 2005	) Examiner: Unassigned
For: CRYSTALLINE FORM OF FATTY ACID AMIDE HYDROLASE (FAAH)	) Our Ref.: TSRI 923.1

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

In recognition of their continuing duty to disclose pursuant to 37 CFR §1.56, Applicants hereby submit the present Information Disclosure Statement and accompanying PTO Form 1449 in compliance therewith.

Applicants understand that the interpretation given to each reference may differ from one individual to another. The PTO is therefore encouraged to independently examine the disclosed references. While the references provided in this Information Disclosure Statement may be material pursuant to 37 CFR §1.56, it shall not be construed to be an admission that the cited information is, or is considered to be, material to patentability

unless specifically designated as such.


Applicants are filing the present statement pursuant to 37 CFR §1.97(b) insofar as this statement is being filed within three months of the filing of the application and/or before the mailing date of a first Office Action.

Also, in accordance with 37 CFR §1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or, that if made, any search was complete or exhaustive, or that no other material information as defined in 37 CFR §1.56 exists.

The Director is hereby authorized to charge our Deposit Account No. 19-0962 in the event that there are any charges associated with the present application.


Respectfully submitted,

April 11, 2007  
Date

  
Michael J. McCarthy, Reg. No. 46,910

THE SCRIPPS RESEARCH INSTITUTE  
Office of Patent Counsel  
10550 North Torrey Pines Road  
Mail Drop TPC-8  
La Jolla, CA 92037  
(858) 784-2937

<b>FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	<b>ATTY DOCKET NO.</b> TSRI 923.1	<b>SERIAL NO.</b> 10/534,766
	<b>APPLICANT</b> Bracey, et al.	
	<b>FILING DATE</b> 11/14/ 2003	<b>GROUP</b> Unassigned



## U.S. PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
		5,221,410	6/22/93	Kushner et al.			
		6,251,931	6/26/01	Boger et al.			
		6,271,015	8/7/01	Gilula et al.			
		6,462,054	10/8/02	Boger et al.			

## FOREIGN PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

	1	Bracey et al., "Structural adaptations in a membrane enzyme that terminates endocannabinoid signaling." <i>Science</i> , 298 , pp. 1793-1796 (2002).
	2	Boger et al., "Exceptionally potent inhibitors of fatty acid amide hydrolase: The enzyme responsible for degradation of endogenous oleamide and anandamide." <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 97, pp. 5044-5049, (2000).
	3	Collaborative Computational Project, Number 4., "The CCP4 Suite: Programs for Protein Crystallography", <i>Acta Cryst.</i> , D50, pp. 760-763 (1994).
	4	Cravatt et al., "Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides." <i>Nature</i> , 384, pp. 83-87, (1996).
	5	Cravatt et al., "Fatty acid amide hydrolase: an emerging therapeutic target in the endocannabinoid system." <i>Current Opinion in Chemical Biology</i> , 7, pp. 469-475, (2003).
	6	Egertová et al., "A new perspective on cannabinoid signalling: complementary localization of fatty acid amide hydrolase and the CB1 receptor in rat brain." <i>Proc. R. Soc. Lond. B. Biol. Sci.</i> , 265, pp. 2081-2085, (1998).
	7	Garavito et al., "Strategies for crystallizing membrane proteins." <i>Journal of Bioenergetics and Biomembranes</i> , 28, pp. 13-27, (1996).
	8	Giang et al., "Molecular characterization of human and mouse fatty acid amide hydrolases." <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 94, pp. 2238-2242, (1997).
	9	Kraulis, "MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures." <i>J. Appl. Cryst.</i> , 24, pp. 946-950, (1991).
	10	Labahn et al., "An Alternative Mechanism for Amidase Signaling Enzymes", <i>J. Mol. Bio.</i> , 322, pp. 1053-1064, (2002).
	11	Makino et al., "Automated flexible ligand docking method and its applications for database search." <i>J. Comput. Chem.</i> , 18, pp. 1812-1825, (1997).
	12	McDonald et al., "Crystal structure of dimeric human ciliary neurotrophic factor determined by MAD phasing." <i>EMBO J.</i> , 14, pp. 2689-2699, (1995).
	13	Merritt et al., "Raster3D: Photorealistic Molecular Graphics", <i>Methods in Enzymology</i> , 277, pp. 505-524, (1997).
EXAMINER		DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

<b>FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	<b>ATTY DOCKET NO.</b> TSRI 923.1	<b>SERIAL NO.</b> 10/534,766
	<b>APPLICANT</b> Bracey, et al.	
	<b>FILING DATE</b> 11/14/ 2003	<b>GROUP</b> Unassigned

## U.S. PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE

## FOREIGN PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

	14	Nicholls et al., "Protein Folding and Association: Insights From Interfacial and Thermodynamic Properties of Hydrocarbons", <i>Proteins Struct. Funct. Genet.</i> , 11, pp. 281-296, (1991).
	15	Patricelli et al., "Comparative Characterization of a Wild Type and Transmembrane Domain-Deleted Fatty Acid Amide Hydrolase: Identification of the Transmembrane Domain as a Site for Oligomerization", <i>Biochemistry</i> , 37, pp. 15177-15187, (1998).
	16	Patricelli et al., "Chemical and Mutagenic Investigations of Fatty Acid Amide Hydrolase: Evidence for a Family of Serine Hydrolases with Distinct Catalytic Properties", <i>Biochemistry</i> , 38, pp. 9804-9812, (1999).
	17	Patricelli et al., "Fatty Acid Amide Hydrolase Competitively Degrades Bioactive Amides and Esters through a Nonconventional Catalytic Mechanism", <i>Biochemistry</i> , 38, pp. 14125-14130, (1999).
	18	Patricelli et al., "Characterization and Manipulation of the Acyl Chain Selectivity of Fatty Acid Amide Hydrolase", <i>Biochemistry</i> , 40, pp. 6107-6115, (2001).
	19	Picot et al., "The X-ray crystal structure of the membrane protein prostaglandin H <sub>2</sub> synthase-1." <i>Nature</i> , 367, pp. 243-249, (1994).
	20	Rice et al., "Single-wavelength anomalous diffraction phasing revisited." <i>Biological Crystallography</i> , D56, pp. 1413-1420, (2000).
	21	Rowland., "Using X-ray crystallography in drug discovery." <i>Current Opinion in Drug Discovery and Development</i> , 5, pp. 613-619 (2002).
	22	Shin et al., "Structure of malonamidase E2 reveals a novel <i>Ser-cisSer-Lys</i> catalytic triad in a new serine hydrolase fold that is prevalent in nature." <i>Embo J.</i> , 21, pp. 2509-2516, (2002).
	23	Sipe et al., "A missense mutation in human fatty acid amide hydrolase associated with problem drug use." <i>Proc. Natl. Acad. Sci U.S.A.</i> , 99, pp. 8394-8399, (2002).
	24	Tieleman et al., "A Molecular Dynamics Study of the Pores Formed by Escherichia coli OmpF Porin in a Fully Hydrated Palmitoylcholine Bilayer", <i>Biophysics Journal</i> , 74, pp. 2786-2801, (1998).
	25	Wendt et al., "Structure and Function of a Squalene Cyclase", <i>Science</i> , 277, pp. 1811-1815, (1997).
EXAMINER		DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.